Effects of aspirin and desmopressin on platelet reactivity in patients undergoing cardiac surgery with extracorporeal circulation

Summary

The effect of desmopressin on platelet function in patients with continued antiplatelet therapy undergoing cardiac surgery is discussed controversially. We assessed platelet reactivity in 86 patients undergoing elective coronary artery bypass grafting (CABG) under extracorporeal circulation. Twenty-nine of these patients were without preoperative antiplatelet therapy (group A), while 57 were treated with acetylsalicylic acid (ASA) 100 mg qd up to the day of surgery. Out of this cohort, 24 patients received no desmopressin perioperatively (group B), whereas 33 patients were treated with desmopressin 0.4 μg/kg after administration of protamine due to increased bleeding tendency (group C). Multiple electrode platelet aggregometry with arachidonic acid as agonist showed a marked decrease of platelet reactivity in patients without antiplatelet therapy immediately after extracorporeal circulation compared to preoperative control (375 ± 227 vs. 749 ± 330 AU*min, p<0.001). Platelet reactivity recovered to preoperative controls in group A at 24 hours after protamine administration (662 ± 295 AU*min). Platelet reactivity in patients on ASA was not decreased further after extracorporeal circulation (group B: 197 ± 126 vs. 251 ± 203 AU*min, p=0.14; group C: 212 ± 100 vs. 245 ± 248 AU*min, p=0.43) and improved significantly within 24 hours. A statistically significant effect of desmopressin, however, could not be determined (group B: 392 ± 223 AU*min; group C: 439 ± 324 AU*min at 24 hours after protamine, p=0.63 for between-subjects contrast). Our data suggest that desmopressin does not affect platelet reactivity in patients on ASA undergoing CABG and is, therefore, not useful in this clinical setting.

Keywords

Acetylsalicylic acid - desmopressin - platelet reactivity - coronary artery bypass grafting

• References

• 1 Ray MJ. et al. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994; 57: 981-986.
• 2 Alghamdi AA. et al. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. J Card Surg 2007; 22: 247-256.
• 3 Herman CR. et al. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg 2010; 89: 397-402.
• 4 Preisman S. et al. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg 2010; 37: 1367-1374.
• 5 Gulbins H. et al. Preoperative platelet inhibition with ASA does not influence postoperative blood loss following coronary artery bypass grafting. Thorac Cardiovasc Surg 2009; 57: 18-21.
• 6 Oscarsson A. et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305-312.
• 7 Salzman EW. et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314: 1402-1406.
• 8 Pleym H. et al. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. Anesth Analg 2004; 98: 578-584.
• 9 Sheridan DP. et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994; 37: 33-36.
• 10 Crescenzi G. et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 2008; 109: 1063-1076.
• 11 Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997; 85: 1258-1267.
• 12 Carless PA. et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004; CD001884.
• 13 Karski JM. et al. The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C). J Cardiothorac Vasc Anesth 1998; 12: 642-646.
• 14 Toth O. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 15 Jambor C. et al. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. Anesth Analg 2009; 109: 25-31.
• 16 Faul F. et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39: 175-191.
• 17 Edmunds Jr. LH. et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982; 83: 805-812.
• 18 Zilla P. et al. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-388.
• 19 Velik-Salchner C. et al. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. Anesth Analg 2009; 108: 1747-1754.
• 20 Pedersen SB. et al. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets 2009; 20: 415-420.
• 21 Frelinger AL. 3rd, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1– and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.
• 22 Ozier Y, Bellamy L. Pharmacological agents: antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol 2010; 24: 107-119.
• 23 Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 01: 682-689.
• 24 Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149-153.
• 25 Reiter RA. et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-4599.
• 26 Peter FW B. et al. Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. Br J Haematol 2002; 117: 658-663.
• 27 Cattaneo M. et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993; 13: 393-397.
• 28 Hanke AA. et al. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry. Anaesthesia 2010; 65: 688-691.
• 29 Sloand EM. et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199-207.
• 30 Tomasiak M. et al. Vasopressin acts on platelets to generate procoagulant activity. Blood Coagul Fibrinolysis 2008; 19: 615-624.
• 31 Ibbotson SH. et al. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on thrombin generation in vitro. Thromb Haemost 1992; 68: 37-39.
• 32 Galvez A. et al. Desmopressin (DDAVP) enhances platelet adhesion to the extra-cellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost 1997; 77: 975-980.
• 33 Strike PC. et al. Exaggerated platelet and hemodynamic reactivity to mental stress in men with coronary artery disease. Psychosom Med 2004; 66: 492-500.
• 34 Gries A. et al. Etomidate and thiopental inhibit platelet function in patients undergoing infrainguinal vascular surgery. Acta Anaesthesiol Scand 2001; 45: 449-457.
• 35 Fourcade O. et al. Propofol inhibits human platelet aggregation induced by proinflammatory lipid mediators. Anesth Analg 2004; 99: 393-398.
• 36 Mochizuki T. et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-785.
• 37 Kawasaki J. et al. The effects of vasoactive agents, platelet agonists and anticoagulation on thrombelastography. Acta Anaesthesiol Scand 2007; 51: 1237-1244.
• 38 Mengistu AM. et al. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery. Anesth Analg 2008; 107: 391-397.
• 39 Karlsson M. et al. Prophylactic Fibrinogen Infusion in Cardiac Surgery Patients: Effects on Biomarkers of Coagulation, Fibrinolysis, and Platelet Function. Clin Appl Thromb Hemost. 2010 e-pub ahead of print.
• 40 Salama ME. et al. Platelet function testing to assess effectiveness of platelet trans-fusion therapy. Transfus Apher Sci 2004; 30: 93-100.
• 41 Sun JC. et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
• 42 Mengistu AM. et al. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth 2008; 22: 40-46.